{"product_id":"human-erc1-pre-designed-sirna-bhn20105079","title":"Human ERC1 Pre-designed siRNA","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eThis pre-designed siRNA set enables sequence-specific knockdown of the human \u003cstrong\u003eERC1\u003c\/strong\u003e gene (NCBI Gene ID: 23085) in human cell lines. Each set is supplied as HPLC-purified, chemically synthesized double-stranded RNA oligonucleotides in lyophilized form, ready for reconstitution and transfection. Two size formats are available: Set A (SI005079A, 3 siRNA sequences at 3×5 nmol) and Set B (SI005079B, 4 siRNA sequences at 4×10 nmol), providing flexibility for screening or extended knockdown studies.\u003c\/p\u003e\n\n\u003ch2\u003eKey Elements and Design Rationale\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple independent sequences:\u003c\/strong\u003e Both sets include 3 or 4 distinct siRNA duplexes targeting different regions of the \u003cstrong\u003eERC1\u003c\/strong\u003e mRNA, increasing the probability of achieving effective knockdown and providing built-in sequence redundancy for experimental confidence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGAPDH positive control:\u003c\/strong\u003e Included in every set to verify transfection efficiency and confirm that the RNAi machinery is functionally active in the cell model used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScrambled negative control (si-NC):\u003c\/strong\u003e A non-targeting scrambled duplex is included to control for non-specific effects of the transfection reagent and dsRNA delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-labeled negative control:\u003c\/strong\u003e Fluorescently labeled NC allows direct visualization of transfection efficiency by fluorescence microscopy or flow cytometry prior to mRNA or protein readout.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHPLC purification:\u003c\/strong\u003e Each duplex is HPLC-purified to remove truncated sequences and reagent impurities that could contribute to off-target effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eBiological Background\u003c\/h2\u003e\n\u003cp\u003eThe \u003cstrong\u003eERC1\u003c\/strong\u003e gene (Gene ID: 23085) encodes a human protein involved in cellular function. siRNA-mediated knockdown of \u003cstrong\u003eERC1\u003c\/strong\u003e is commonly applied to assess the contribution of this gene to cell proliferation, signaling, or metabolic pathways depending on the biological context. The RNA interference (RNAi) pathway exploits the RISC complex: after cellular entry, the sense (passenger) strand is degraded, and the antisense (guide) strand directs RISC-mediated cleavage of complementary \u003cstrong\u003eERC1\u003c\/strong\u003e mRNA, leading to mRNA degradation and reduced protein expression. This approach is widely used to model loss-of-function phenotypes in cultured human cell lines.\u003c\/p\u003e\n\n\u003ch2\u003eResearch Relevance and Current Trends\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFunctional genomics screens:\u003c\/strong\u003e Pre-designed siRNA sets targeting individual genes such as \u003cstrong\u003eERC1\u003c\/strong\u003e are routinely used in arrayed or pooled functional screens to identify gene dependencies in cancer cell lines, primary cells, and disease models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePathway validation:\u003c\/strong\u003e After identifying candidate genes by transcriptomics or proteomics, researchers commonly use siRNA knockdown to confirm the functional role of a target like \u003cstrong\u003eERC1\u003c\/strong\u003e before advancing to stable KO models.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTarget prioritization:\u003c\/strong\u003e The availability of multiple non-overlapping siRNA sequences per set supports orthogonal knockdown confirmation, a best practice for reducing false-positive conclusions in gene function studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eCommon Research Applications\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA knockdown validation by RT-qPCR:\u003c\/strong\u003e Following transfection, mRNA levels of \u003cstrong\u003eERC1\u003c\/strong\u003e are typically measured at 24–72 h post-transfection using RT-qPCR, with knockdown efficiency calculated relative to a reference gene. Multiple siRNA sequences allow identification of the most effective duplex for downstream studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProtein-level knockdown by Western blot:\u003c\/strong\u003e Knockdown at the protein level is assessed 48–96 h post-transfection by Western blot or ELISA. Note that mRNA and protein knockdown kinetics may differ depending on protein turnover rate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePhenotypic assays:\u003c\/strong\u003e Once knockdown is confirmed, researchers use the optimized siRNA sequence to assess effects on cell viability, proliferation, migration, apoptosis, or signaling pathway activation depending on the role of ERC1 in the model studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFAM-NC-guided optimization:\u003c\/strong\u003e The FAM-labeled negative control enables parallel assessment of transfection efficiency (≥80% is typically required for reliable knockdown results) before committing target-specific siRNA to experiments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eNotes for Experimental Interpretation\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransfection efficiency:\u003c\/strong\u003e Knockdown outcomes are highly dependent on achieving adequate transfection efficiency. The FAM-labeled NC should be used first to optimize reagent and siRNA concentrations for the specific cell line used.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-target effects:\u003c\/strong\u003e Even HPLC-purified siRNAs can exhibit sequence-dependent off-target activity. Inclusion of the scrambled negative control and comparison of multiple independent ERC1 siRNA sequences helps distinguish on-target from off-target phenotypes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003emRNA vs. protein knockdown:\u003c\/strong\u003e High mRNA knockdown does not always correlate with equivalent protein reduction, depending on protein half-life. Both mRNA (RT-qPCR) and protein (WB) readouts are recommended for complete characterization.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCell-type considerations:\u003c\/strong\u003e Knockdown efficiency and phenotypic outcomes may vary across different human cell lines due to differences in transfection efficiency, RNAi machinery activity, and baseline ERC1 expression levels.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003ch3\u003eSet A (SI005079A) — 3 siRNA sequences × 5 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERC1 siRNA-1: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERC1 siRNA-2: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERC1 siRNA-3: 5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eSet B (SI005079B) — 4 siRNA sequences × 10 nmol\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003eHuman ERC1 siRNA-1: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERC1 siRNA-2: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERC1 siRNA-3: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eHuman ERC1 siRNA-4: 10 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eGAPDH siRNA Positive Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003esiRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n  \u003cli\u003eFAM-labeled siRNA Negative Control: 2.5 nmol (HPLC)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- Sources (internal):\n- NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\/23085\n- Elbashir SM et al. (2001) Nature. https:\/\/doi.org\/10.1038\/35078107\n- Fire A et al. (1998) Nature. https:\/\/doi.org\/10.1038\/35888\n- Reynolds A et al. (2004) Nature Biotechnology. https:\/\/doi.org\/10.1038\/nbt936\n- Jackson AL \u0026 Linsley PS (2010) Nature Reviews Drug Discovery. https:\/\/doi.org\/10.1038\/nrd3054\n- Kaelin WG (2012) Science. https:\/\/doi.org\/10.1126\/science.1225150\n--\u003e","brand":"GenCefe Biotech","offers":[{"title":"3 × packageA","offer_id":53165429653869,"sku":"SI005079A","price":279.0,"currency_code":"USD","in_stock":true},{"title":"4 × packageB","offer_id":53165514686829,"sku":"SI005079B","price":399.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/pre-designed_siRNA_A-3_vials_c4de3638-6136-4961-90bb-ed0dd09ee21f.png?v=1774683684","url":"https:\/\/www.ebiohippo.com\/products\/human-erc1-pre-designed-sirna-bhn20105079","provider":"BioHippo","version":"1.0","type":"link"}